The UK government has invested an extra £100m in a new state-of-the-art centre to scale up Covid-19 vaccine and gene therapy manufacturing. It says this will be vital for the UK’s ability to respond to viruses like the new coronavirus and other potential future pandemics. Rod Schregardus, a pharmaceutical manufacturing expert at The Access Group says this is great news, but warns that consideration must also be given now to the facility’s manufacturing planning and scheduling systems to ensure it can meet its full potential.
Located in Braintree, Essex, the Government's new COVID-19 vaccine manufacturing facility is due to open in December 2021. With the capacity to produce millions of doses a month, the new site will ensure the UK can manufacture vaccines for a whole range of emerging diseases beyond this crisis and far into the future.
This is a prudent step, as the incidence of outbreaks of new diseases are on the increase. Not all diseases will threaten the UK in the same way that Covid-19 has, however scientists agree that increased urbanisation, deforestation, human-to-animal contact and global travel combine to make a dangerous cocktail.
No one can be sure what challenges we will face in the future. And there are a lot of unknowns when it comes to Covid-19 vaccines too. There’s a need to be prepared but there are also a lot of variables which make it impossible to make rock-solid plans. For example, we don’t yet know how long it will take to make a batch of any new vaccine - it could be six weeks or it could be 36 weeks as there is no precedent. Despite this, it’s essential that we have the correct infrastructure in place to respond quickly when necessary, ensuring we can provide a dose of vaccine for every person in the country as soon as possible.
The global response to this outbreak by the international scientific community has been extraordinary; with more than 140 separate teams of researchers working on a vaccine. Several vaccines were available just months after the emergence of the new Coronavirus, which has impacted pretty much all 8 billion human lives on the planet.
That said, how did we translate the amazing progress made into readily available doses of inexpensive vaccines in very large numbers? The pharmaceutical industry is highly complex with many interdependent processes throughout the manufacturing process. Ordinarily a product lifecycle can span four decades from R&D to sales. This makes the rapid manufacture of a vaccine en-masse a relatively alien concept.
All drugs go through a rigorous approvals process, but this was speeded up where possible. For example, there were lots more volunteers taking part in trials than ordinarily would be the case because it’s been so high profile - catalysts such as this likely made this the fastest development programme ever undertaken.
So, once vaccines are approved, where do we go next? We’d argue that having the right technology and systems in place to ensure the best process will be as important as having the means of production on standby. This is needed to ensure enough stock can be manufactured quickly enough to protect the population and limit further damage to society.
The use of an advanced planning and scheduling (APS) system is critical in creating a single real-time plan to reduce lead times and optimise resources. The granularity of data far exceeds that of spreadsheets and users are able to use this to model scenarios based on resources, constraints and process time, in order to make more effective decisions.
So, what are the critical elements to ensure we maximise the new facility’s full potential?
Spreadsheets are complex, inconsistent, prone to errors and out-of-date - not to mention time-consuming. With no visibility over processes, they are unable to show where there is capacity. Having a single source of data to base decisions on, means no time lag and the assurance of a standardised dataset, leading to one single version of the truth.
This is key to ramping up vaccine production quickly. After all, without a firm basis of evidence, how can managers make informed decisions that ultimately drive performance? This will save all important time and reduce the likelihood of planning mistakes and delays - set-backs we can ill-afford.
As there are so many unknowns, setting the facility up to enable a 360-degree view will enable planners to act quickly and communicate any changes to drive productivity. This means implementing an APS which has powerful planning capabilities that help production managers coordinate each stage of manufacturing.
Crucially, this can be fundamental for scaling up operations in a new facility such as the one planned in Essex. ‘What-if?’ scenario planning means we’ll be able to model different options and understand the impact of different variables in the production process, including the resources needed and whether bottlenecks are likely to occur.
As we understand more about the production process, planners will be able to use this approach to plot the best path to manufacture the greatest amount of vaccine in the shortest space of time.
Alongside planning, there will also need to be a scheduling function which facilitates production constraints (materials, workforce and so on) to create and optimise a schedule. This will enable the team to intelligently manage workloads, taking the availability of different resources into account and helping to facilitate different production routes where necessary.
In addition to the investment in new manufacturing infrastructure, the Government has also made an additional £4.7m available for new training facilities, and an online learning platform, to boost vaccines as well as cell and gene therapy skills.
It’s important to note that having advanced systems in place will not replace the experience of the planning team. However, it will do the heavy lifting for planners and supervisors, allowing them to focus on ensuring the facility reaches its maximum potential as soon as possible, using their knowledge and expertise.
Let’s make sure we guarantee that those at the helm, when this facility is complete, will be spending less time accessing spreadsheets and more on completing the task at hand. Only when there is a single version of the truth will they identify how to truly maximise resources and yield, while eliminating the human errors that invariably come as a result of manual processes.
There will be more than enough to think about for them given the momentous task of planning the manufacture of enough vaccines for the entire country now and in the future.
3 ways in which using Excel for production planning is hurting your business
The use of Excel spreadsheets for production planning and scheduling is surprisingly widespread in the manufacturing environment. The software is familiar to many planners, and it can be seen as a quick and easy option when it comes to production scheduling. However, there are sophisticated software solutions are available which could transform the way you manage production planning. Is it time to leave Excel behind?
Case Study: Orchestrate Puts Biopharma Company on Track to Achieve Growth
Having scaled up significantly, the global pharmaceutical company wanted to maximize capacity and get the most from every batch.
Read case study
Manufacturing challenges for the pharmaceutical industry
The outbreak has shone a light on the supply chain and its capabilities. With some nations struggling to access the resources needed to manufacture health care products already on the market - let alone look to deliver vast amounts of vaccines and treatments at large scale - what does the future hold for pharmaceutical manufacturing?
Read case study
Pharma Manufacturing Pain Points: How a clear strategy could be the vaccine your company needs
Working within the pharmaceutical industry, you will know that rapid growth in the market brings with it a number of challenges. We’ve unpacked some of the pharma challenges currently affecting the sector, along with some perfectly prescribed antidotes to fight them.
The importance of production capacity and strategic planning in pharmaceutical manufacturing
Ongoing development of manufacturing sites is essential to provide future-state readiness of a continually evolving business environment.
Case Study: Global pharmaceutical company use Access planning scheduling software for pandemic planning
Using Access Orchestrate, Baseline Controls’ consultants were able to conduct a detailed analysis of capacity long before full production had begun. Since Access Orchestrate was first implemented to prove capacity, the pharmaceutical company has scaled up its use of the software across the site for day-to-day production scheduling.
Read case study
Case Study: Major international pharmaceutical company uses Access Planning and Scheduling software to drive strategic initiatives
Pharmaceutical companies using Access Orchestrate as their day-to-day production scheduling and capacity tool are also exploiting its functionality to address key strategic issues.
Read case study
Case Study: Day-to-day production scheduling for international pharmaceutical company
In this case study, we learn how one of the world’s largest pharmaceutical companies is using Access Orchestrate Planning and Scheduling software every day in a production facility producing vaccines and self-injected prescription medicines.
Read case study
Case Study: Greater management, control and visualisation for Surepharm Services
Access Orchestrate helps Surepharm Services with greater management, control and visualisation over orders, which has improved production, as well as heightened morale and collaboration.
Read case study
Efficiency: The Key To Sustainable Manufacturing In Pharma
Terms such as ‘efficiency’ and ‘sustainability’ have long been key talking points for pharma manufacturing. Indeed, in an industry that’s facing increasingly complex pressures, particularly as it adjusts to the changing demands seen as a result of Covid-19, the need for resources and processes that reduce wastage and maximise productivity, profitability and reliability are essential.
Case Study: Automated Scheduling Set to Reduce Costs and Drive Up Revenue at Major Biopharma Firm
Access Orchestrate helps a major US Biopharma company with greater management, control and visualisation over orders, which has improved production, as well as heightened morale and collaboration.
Read case study
Precision Medicines: Adapting Manufacturing For The Super Small Batch
There’s a buzz on the pharmaceutical manufacturing block about personalized medicine. Its promise will not have escaped the notice of most readers, growing in prominence with very real potential to treat previously incurable diseases and minimize human suffering on a grand scale.
Read case study